

# פרסומי הקבוצה הישראלית



# **Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial**

*Hermann Einsele, Jesús San-Miguel, Binod Dhakal, Cyrille Touzeau, Xavier Leleu, Niels WCJ van de Donk, Surbhi Sidana, Albert Oriol, Yael C Cohen, Simon J Harrison, María-Victoria Mateos, Joaquín Martínez-López, Paolo Corradini, Lionel Karlin, Diana Chen, Quanlin Li, Tzu-min Yeh, Katherine Li, Vicki Plaks, Ana Slaughter, Carolina Lonardi, Nina Benachour, Arnab Ghosh, Martin Vogel, Jordan M Schechter, Nikoletta Lendvai, Mythili Koneru, Nitin Patel, Erika Florendo, Phoebe Joy Ho, Rakesh Popat*



CRITICAL REVIEW OPEN ACCESS

## Extramedullary Disease—Achilles Heel in Myeloma?

Shaji Kumar<sup>1</sup>  | Joshua Richter<sup>2</sup>  | Saad Z. Usmani<sup>3</sup> | Yael C. Cohen<sup>4,5</sup>  | Jing Christine Ye<sup>6</sup> | María-Victoria Mateos<sup>7</sup> | Vania Hungria<sup>8</sup>  | Elena Zamagni<sup>9</sup>

<sup>1</sup>Mayo Clinic Rochester, Rochester, Minnesota, USA | <sup>2</sup>Mount Sinai School of Medicine, New York, New York, USA | <sup>3</sup>Memorial Sloan Kettering Cancer Center, New York, New York, USA | <sup>4</sup>Tel Aviv Sourasky (Ichilov) Medical Center, Tel Aviv, Israel | <sup>5</sup>Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel | <sup>6</sup>MD Anderson Cancer Center, University of Texas, Houston, Texas, USA | <sup>7</sup>Hospital of Salamanca/IBSAL/CIC/CIBERONC, Salamanca, Spain | <sup>8</sup>Clinica Médica São Germano, São Paulo, Brazil | <sup>9</sup>University of Bologna, Bologna, Italy

**Correspondence:** Shaji Kumar ([kumar.shaji@mayo.edu](mailto:kumar.shaji@mayo.edu))

**Received:** 2 September 2025 | **Revised:** 22 October 2025 | **Accepted:** 31 October 2025

















**Keywords:** bispecific antibodies | immunotherapy | paramedullary | relapsed myeloma

ORIGINAL ARTICLE

## Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab

S. Kumar,<sup>1</sup> M.-V. Mateos,<sup>2-5</sup> J.C. Ye,<sup>6</sup> S. Atrash,<sup>7</sup> H. Magen,<sup>8</sup> H. Quach,<sup>9</sup>  
M.P. Chu,<sup>10</sup> S. Trudel,<sup>11</sup> J. Richter,<sup>12</sup> P. Rodríguez-Otero,<sup>13</sup> H. Chuah,<sup>14</sup>  
M. Gatt,<sup>15</sup> E. Medvedova,<sup>16</sup> S. Raza,<sup>17</sup> D.H. Yoon,<sup>18</sup> T. Ishida,<sup>19</sup> J.V. Matous,<sup>20</sup>  
L. Rosiñol,<sup>21</sup> K. Onodera,<sup>22</sup> E. Scott,<sup>23</sup> C. Heuck,<sup>23</sup> J. Zhang,<sup>23</sup> T. Henninger,<sup>24</sup>  
L. O'Rourke,<sup>23</sup> P. Thakkar,<sup>24</sup> M. Festa,<sup>25</sup> L. Huang,<sup>23</sup> J. Zhou,<sup>23</sup> M. Takamoto,<sup>26</sup>  
L. Pei,<sup>24</sup> J. Lu,<sup>27</sup> N. Au,<sup>23</sup> M. Krevvata,<sup>23</sup> S.Z. Usmani,<sup>28</sup> and Y.C. Cohen,<sup>29</sup>  
for the RedirectT-1 Investigators Study Group\*

# Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study

Rakesh Popat, MD, PhD<sup>1</sup> ; Meral Beksac, MD<sup>2</sup> ; Meletios A. Dimopoulos, MD<sup>3,4</sup> ; Moshe E. Gatt, MD<sup>5</sup> ; Francesca Gay, MD<sup>6</sup> ; Jae-Cheol Jo, MD, PhD<sup>7</sup> ; Prashant Kapoor, MD<sup>8</sup> ; Eirini Katodritou, MD, PhD<sup>9</sup> ; K. Martin Kortüm, MD<sup>10</sup> ; Silvia Ling, PhD, MBBS<sup>11</sup> ; Chandramouli Nagarajan, MD<sup>12</sup> ; Kenshi Suzuki, MD, PhD<sup>13</sup>; Lugui Qiu, MD<sup>14</sup>; Maika Onishi, MD<sup>15</sup>; Grace Ku, MD<sup>15</sup> ; Monique Dail, PhD<sup>15</sup> ; Nabanita Mukherjee, PhD<sup>16</sup>; Jeremy A. Ross, PhD<sup>16</sup>; Mohamed Ali Badawi, PhD<sup>16</sup>; Mary Jean Fusco, MD<sup>16</sup>; Edyta Dobkowska, MD<sup>17</sup>; Emma Arriola, PhD<sup>18</sup>; Orlando F. Bueno, MD, PhD<sup>16</sup>; Nizar J. Bahlis, MD<sup>19</sup> ; Shinsuke Iida, MD<sup>20</sup> ; Philippe Moreau, MD<sup>21</sup>; Jason Valent, MD<sup>22</sup>; and María-Victoria Mateos, MD, PhD<sup>23</sup> 

DOI <https://doi.org/10.1200/JCO-25-00924>

RESEARCH








# Outcomes in patients with relapsed/refractory multiple myeloma with extramedullary disease: a meta-analysis

Peter M. Voorhees<sup>1</sup> · Shaji Kumar<sup>2</sup> · Saad Z. Usmani<sup>3</sup> · Jing Christine Ye<sup>4</sup> · Yael C. Cohen<sup>5,6</sup> · Emma Scott<sup>7</sup> · Robin L. Carson<sup>7</sup> · Christoph Heuck<sup>7</sup> · Ryan Gan<sup>8</sup> · Benjamin Ackerman<sup>8</sup> · Jenny Zhang<sup>7</sup> · Eleanor Caplan<sup>9</sup> · Trilok Parekh<sup>8</sup> · María-Victoria Mateos<sup>10</sup>

Received: 27 August 2025 / Accepted: 19 October 2025 / Published online: 3 December 2025  
© The Author(s) 2025

Article

# High Implementation Adherence to Lenalidomide in Multiple Myeloma

Irina Amitai <sup>1,2,†</sup>, Hila Magen <sup>1,2,†</sup> , Avi Leader <sup>2,3,4</sup>, Antoine Pironet <sup>5</sup> , Eric Tousset <sup>5</sup>, Alon Rozental <sup>2,3</sup>, Sabina De Geest <sup>6,7</sup> , Iuliana Vaxman <sup>2,3</sup>, Pia Raanani <sup>2,3</sup>  and Arnon Nagler <sup>1,2,\*</sup> 

<sup>1</sup> Division of Hematology, Chaim Sheba Medical Center, Ramat-Gan 5262000, Israel; irina.amitai@sheba.health.gov.il (I.A.); hila.magen@sheba.health.gov.il (H.M.)

<sup>2</sup> The Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv 6997801, Israel; leadera@mskcc.org (A.L.); alon.rozental@clalit.org.il (A.R.); juliava1@clalit.org.il (I.V.); praanani@012.net.il (P.R.)

<sup>3</sup> Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petah Tikva 6356710, Israel

<sup>4</sup> Department of Medicine, Hematology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA

<sup>5</sup> AARDEX Group, 4432 Ans, Belgium; antoine.pironet@aardexgroup.com (A.P.); eric.tousset@aardexgroup.com (E.T.)

<sup>6</sup> Institute of Nursing Science, Department Public Health, University of Basel, 4056 Basel, Switzerland; sabina.degeest@unibas.ch

<sup>7</sup> Academic Centre of Nursing and Midwifery, Department Public Health and Primary Care, 3000 Leuven, Belgium

\* Correspondence: arnon.nagler@sheba.health.gov.il; Tel.: +972-526667180; Fax: +972-35304792

† These authors contributed equally to this work.

Article

# High Rate of Cytokine Release Syndrome-Related Coagulopathy with Low Incidence of Bleeding and Thrombosis in Patients Treated with B-Cell Maturation Antigen (BCMA)-Targeted Chimeric Antigen Receptor T-Cells (CAR-T)

Ariela Arad <sup>1,2,†</sup> , Maya Katz <sup>2,†</sup>, Eyal Lebel <sup>2,3</sup> , Yosef Kalish <sup>1,2</sup>, Miri Assayag <sup>2,3</sup>, Batia Avni <sup>2,3</sup> , Shlomo Elias <sup>2,3</sup>, Sigal Grisariu <sup>2,3</sup>, Ela Shai <sup>1,2</sup>, Shlomit Kfir-Erenfeld <sup>2,3</sup>, Nathalie Asherie <sup>2,3</sup> , Moshe E. Gatt <sup>1,2</sup> , Polina Stepensky <sup>2,3</sup> and Eran Zimran <sup>1,2,3,\*</sup> 

<sup>1</sup> Department of Hematology, Hadassah Hebrew University Medical Center, Jerusalem 91200, Israel

<sup>2</sup> Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem 91904, Israel

<sup>3</sup> Department of Bone Marrow Transplantation and Cancer Immunotherapy, Hadassah Hebrew University Medical Center, Jerusalem 91200, Israel

\* Correspondence: eran.zimran@gmail.com; Tel.: +972-50-4048732

† These authors contributed equally to this work.

ARTICLE IN PRESS

JID: CLML

[mNS;October 31, 2025;11:27]

**Original Study**

# Advanced Multicolor Flow Cytometry Method for Multiple Myeloma

Noa Ofir,<sup>1</sup> Ety Rozenberg,<sup>1</sup> Omri Sharabi,<sup>1</sup> Miri Zektser,<sup>2</sup> Ory Rouvio,<sup>2,3</sup> Roi Gazit<sup>1</sup>

# Acta Haematologica

Acta Haematol , DOI: 10.1159/000550220

Received: November 6, 2025

Accepted: December 17, 2025

Published online: December 24, 2025

## **Post-transplant lymphoproliferative disorder (PTLD) following heart transplantation presenting as a retroperitoneal plasmacytoma – a case report and review of the literature**

Vilian Y, Sherban A, Goldberg E, Wax T, Cohen E, Hezkelo N, Sheena L, Vaxman I, Raanani P, Krause I, Goldberg I

# יוזמות למחקרים משותפים של הקבוצה

# Talquetamab for AL amyloidosis

- Treatment options for R/R AL amyloidosis progressing on ANDROMEDA are limited, especially for patients without t(11;14) translocation. Talquetamab, a CD3/GPRC5D bispecific antibody, showed significant efficacy for RRMM. Toxicity is notable for dysgeusia, weight loss and dermatologic disorders. Other immunotherapies, such as CAR-T and Teclistamab, have been successfully used for AL amyloidosis patients
- No data on TAL administration for AL amyloidosis
- AIM: to assess efficacy and safety of all Israeli AL amyloidosis treated with Talquetamab for AL amyloidosis

# Real-World Comparison of Kyprolis-based Regimens vs. PVd in RRMM

- **Retrospective** multi-center study.
- Aim: To compare toxicity and efficacy of **KPd/KCd/Kd vs. PVd**.
- Inclusion: MM patients who had at least one previous line of therapy, receiving therapy with KPd, KCd, Kd or PVd.
- Exclusion: AL Amyloidosis.
- Main outcomes:
  - Hematological and non-hematological toxicities.
  - PFS
  - OS

Renana Robinson: 052-7018035, [renana.robinson@gmail.com](mailto:renana.robinson@gmail.com)

## The effect of steroid dose in frontline induction for AL amyloidosis in the novel agents' era

- **Aim:** To assess the effect of steroid dose in frontline induction for AL amyloidosis in the novel agents' era on key efficacy and toxicity outcomes
- **Hypothesis:** Steroids dose are commonly decreased in real-world induction for AL. This is associated with less toxicity and similar efficacy
- **Methods:** Retrospective multi-center study- Israeli multiple myeloma (MM) group
- **Included:** All AL amyloidosis patients treated in Israeli centers, receiving frontline therapy with bortezomib-based therapy (and/or dara-based).
- Data on steroid exposure, efficacy and toxicity is collected and analyzed

# Israel Early access program - open 27/5/2025

Early access to innovation for patients, and early hands-on experience for EEs

## Inclusion criteria

### Diagnosis of MM and/or plasma cell dyscrasia and either:

- For combination with bortezomib/dexamethasone

**BVd**


- Previously treated with **at least 1 but no more than 2** prior lines of MM therapy and
- Must have documented disease progression during or after their most recent therapy

- For combination with pomalidomide/dexamethasone

**BPd**

- Previously treated with **at least 1 but no more than 2 prior lines** of MM therapy, including a lenalidomide-containing regimen (lenalidomide must have been administered for at least 2 consecutive cycles) and
- Must have documented disease progression during or after their most recent therapy

- Note: Induction + ASCT + maintenance is 1 line of therapy. Patients treated with lenalidomide  $\geq 10$  mg daily for at least 2 consecutive cycles are eligible



מרכז רפואי	מספר מטופלים
איכילוב	28
ברמל	13
סורוקה	12
בילינסון	7
הלל יפה	5
הדסה	4
אסותא אשדוד	3
וולפסון	1
לניאדו	1
מאיר	1
רמב"ם	1
סה"כ מטופלים	76

**76 patients**